Roth Capital raised the firm’s price target on iRadimed (IRMD) to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: